pCDH-UbC-MCS-IRES-GFP Cloning and Expression Lentivector

pCDH-MSCV-MCS-EF1α-Puro Cloning and Expression Lentivector

pCDH-MSCV-MCS-EF1α-GFP Cloning and Expression Lentivector

pCDH-MSCV-MCS-EF1α-GFP+Puro Cloning and Expression Lentivector

pCDH-MSCV-MCS-IRES-GFP Cloning and Expression Lentivector

pCDH-EF1α-MCS-(PGK-Puro) Bidirectional Promoter Cloning and Expression Lentivector

pCDH-EF1α-MCS-(PGK-GFP) Bidirectional Promoter Cloning and Expression Lentivector

pCDH-EF1α-MCS-(PGK-GFP-T2A-Puro) Bidirectional Promoter Cloning and Expression Lentivector

pCDH-EF1α-MCS-T2A-RFP (PGK-Puro) Bidirectional Promoter Cloning and Expression Lentivector

pCDH-EF1α-MCS-T2A-GFP (PGK-Puro) Bidirectional Promoter Cloning and Expression Lentivector

pCDH-CMV-MCS-EF1α-RFP Cloning and Expression Lentivector

pCDH-CMV-MCS-EF1α-GreenPuro Cloning and Expression Lentivector

pCDH-CMV-MCS-EF1α-Neo Cloning and Expression Lentivector

pCDH-CMV-MCS-EF1α-Hygro Cloning and Expression Lentivector

pCDH-CMV-MCS-EF1α-RFP+Puro Cloning and Expression Lentivector

pCDH-MCS-T2A-Puro-MSCV Cloning and Expression Lentivector

pCDH-MCS-T2A-copGFP-MSCV Cloning and Expression Lentivector

pCDH-CMV-MCS-T2A-copGFP Cloning and Expression Lentivector

pCDH-EF1α-MCS*-T2A-GFP Cloning and Expression Lentivector

pCDH-EF1α-MCS-T2A-Puro Cloning and Expression Lentivector

pCDH-EF1α-MCS-IRES-GFP Cloning and Expression Lentivector

pCDH-EF1α-MCS-IRES-RFP Cloning and Expression Lentivector

pCDH-EF1α-MCS-IRES-Puro Cloning and Expression Lentivector

pCDH-EF1α-MCS-IRES-Neo Cloning and Expression Lentivector

pCDH-EF1α-MCS-BGH-PGK-GFP-T2A-Puro Cloning and Expression Lentivector

pCDH-UbC-MCS-EF1α-Hygro Cloning and Expression Lentivector

pCDH-CMV-MCS Cloning and Expression Lentivector

pCDH-CMV-MCS2 Cloning and Expression Lentivector

pCDH-EF1α-MCS Cloning and Expression Lentivector

pCDH-CMV-MCS-EF1α-Puro Cloning and Expression Lentivector

pCDH-CMV-MCS-EF1α-copGFP Cloning and Expression Lentivector

  • Chu, J, et al. (2014) CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014 Apr 1; 28(4):917-27. PM ID: 24067492